Hello, this is Daily Stock, delivering precise insights into key market trends and corporate value.
[이미지: /stdaily/uploads/202609/gen_6aa1041ba21cc2.58716536.png]
Executive Summary
Samsung Biologics (207940) is solidifying its "super-gap" dominance in the global contract development and manufacturing organization (CDMO) market as it begins the commercial ramp-up of Plant 5, the core anchor of its Second Bio Campus in Songdo, Incheon.
With the 180,000-liter (L) Plant 5 entering full-scale operations, the company's total production capacity has reached 784,000 liters, firmly cementing its status as the world's No. 1 capacity holder.
As of the first half of 2026, cumulative orders on a consolidated basis surpassed $21.7 billion (approx. KRW 30 trillion). With Plants 1 through 4 operating at full capacity, annual revenue is increasingly expected to break through the KRW 5 trillion threshold.
Portfolio diversification is also accelerating with the recent addition of a production site in Rockville, Maryland, and the acquisition of Switzerland-based PolyPeptide to expand into the GLP-1 obesity peptide segment.
However, a temporary breathing spell in new large-scale order announcements during the first half and valuation adjustment pressures stemming from global macro uncertainties remain key short-term variables.
---
Current Market Context
The domestic equity market saw the KOSPI close at 7,051.64, undergoing an absorption phase focused on semiconductors and large-cap growth stocks.
The KOSDAQ closed at 830.37, while the US Nasdaq stood at 26,421.41. In the Seoul foreign exchange market, the USD/KRW currency pair finished at 1,336.60 won.
According to Daily Stock's proprietary Fear & Greed Index, the KOSPI Fear & Greed Index currently sits at Neutral (50.2), showing a gradual recovery from Fear (30.5) one week ago, Fear (21.7) one month ago, and Neutral (53.7) three months ago.
Conversely, the Nasdaq Fear & Greed Index is at Neutral (40.5), showing lingering caution compared to Fear (33) one week ago, Greed (64.4) one month ago, and Neutral (57.9) three months ago.
Amid these macroeconomic conditions, the USD/KRW exchange rate in the mid-1,330 won range provides favorable profitability for large CDMO companies whose settlements are overwhelmingly denominated in US dollars.
As of the market close on September 9, 2026, the exact closing price for Samsung Biologics is "unconfirmed for the day (based on latest available data)," but the stock has recently been testing new order momentum within a trading band of KRW 1.3 million to 1.4 million.
Currently, Samsung Biologics' Plant 5 is expected to recognize commercial revenue sequentially starting in Q3 following validation batches. The Rockville facility acquired from GSK has also begun to be recognized on a consolidated basis.
[이미지: /stdaily/uploads/202609/gen_6aa104266b6b87.92757029.png]
---
Financial Analysis
In the first half of 2026, Samsung Biologics posted record half-year consolidated revenue of KRW 2.5780 trillion and operating profit of KRW 1.1672 trillion.
Second-quarter consolidated revenue reached KRW 1.3209 trillion and operating profit hit KRW 586.4 billion, surging 30.2% and 23.0% year-over-year, respectively.
Despite upfront depreciation and fixed costs related to Plant 5 operational preparations and US facility acquisitions, the company maintained an overwhelming operating profit margin (OPM) of around 44%.
| Key Financial Indicators | FY2024 | FY2025 (Est.) | H1 2026 (Cumulative) | Notes |
|---|---|---|---|---|
| **Consolidated Revenue** | KRW 3.6946T | ~KRW 4.5000T | KRW 2.5780T | Annual KRW 5T within reach |
| **Operating Profit** | KRW 1.1137T | ~KRW 1.7000T | KRW 1.1672T | First time exceeding KRW 1T in a half-year |
| **Operating Margin (OPM)** | ~30.1% | 37–38% range | ~45.3% | Driven by full operation of Plants 1–4 |
| **Debt Ratio** | ~58% | ~53% | 51.3% | Sustaining sound balance sheet |
| **Cumulative Orders** | ~$16.0B | ~$19.5B | $21.7B (~KRW 30T) | 115 CMO, 176 CDO contracts |
As of the end of H1, the borrowing ratio stood at just 11.5%, maintaining solid fundamentals under a net cash structure.
Of the capital raised through a KRW 3 trillion rights offering, roughly 90% is allocated to the acquisition of Switzerland's PolyPeptide, with portions directed toward funding expansions at the Second Bio Campus.
---
Valuation
Backed by partnerships with global big pharma and the world's largest manufacturing capacity, Samsung Biologics has commanded the highest valuation premium in the domestic large-cap biopharma sector.
While global CDMO peer Lonza trades at a 12-month forward EV/EBITDA multiple of 20–25x, Samsung Biologics trades around 25–30x, fueled by structural growth expectations from Plant 5 and future Plant 6 expansions.
Although its valuation is elevated compared to the overall KOSPI benchmark, the sustained OPM above 40% and earnings stability backed by long-term supply agreements serve as the core rationale for this premium.
However, amid recent capex re-evaluations by global pharma companies and concerns over a near-term lull in massive new contract announcements, the consensus target price has adjusted downward from the KRW 2.1M–2.3M range to KRW 1.8M–2.0M.
Justifying the current valuation hinges directly on the actual utilization ramp-up rate of Plant 5 and the scale of additional major contract announcements within the year.
---
Expert & Institutional Analysis
Securities analysts broadly agree that the ramp-up of Plant 5 and normalization of the US Rockville facility will elevate second-half earnings volume to the next level.
Jun-young Kim, an analyst at Meritz Securities, favorably evaluated Plant 5's transition to validation batches and the Rockville plant's potential quarterly revenue contribution of over KRW 100 billion. However, he noted that tangible announcements of new large-scale contracts are essential for a sustained trend reversal in share price.
Brokerages including Mirae Asset Securities and Hyundai Motor Securities slightly deferred their assumptions for Plant 5's full-utilization timing, citing that confirmed new orders in H1 stood at around $500 million, resetting target prices to the KRW 1.9M–2.1M range.
In terms of institutional and foreign capital flows, passive inflows into top KOSPI market-cap names alongside selective buying within the CDMO sector have been observed under the mid-1,330 won exchange rate environment.
In particular, market consensus anticipates sustained mid- to long-term interest in the company as a key beneficiary absorbing diverted demand from Chinese competitors (such as WuXi Biologics) driven by the legislative progress of the US Biosecure Act.
---
Risk Factors
The most immediate short-term risk is the potential delay in contract decision-making by global big pharma.
Due to uncertainties surrounding US trade policies and global healthcare policy dynamics, clients have shown a tendency to push back timelines for signing large CDMO contracts.
Second is the escalating burden of fixed costs.
With the full commercial operation of Plant 5, preparations to break ground on Plant 6, and capital outlays for the PolyPeptide acquisition coinciding, upfront depreciation and operational expenditures could temporarily compress the operating margin.
Third is currency volatility in the USD/KRW exchange rate.
While the current high exchange rate around 1,336 won benefits near-term earnings, a rapid descent in the exchange rate triggered by Bank of Korea monetary policy pivots or US interest rate cuts could reduce KRW-denominated revenues.
Finally, investors need to monitor whether the roughly KRW 150 billion in production delays caused by H1 union strikes will be smoothly recouped through second-half schedule adjustments.
---
Investment Perspective
Samsung Biologics stands at the threshold of structural growth, anchored by an unmatched production capacity of 784,000 liters and a formidable $21.7 billion order backlog.
[이미지: /stdaily/uploads/202609/gen_6aa10430817f50.46767544.png]
In the short term, investors should keep potential price consolidation in mind due to the H1 order lull and the rights offering.
However, if commercial batch revenues from Plant 5 begin showing up tangibly in the consolidated income statement during the second half, and new European contracts materialize following the launch of the Netherlands sales office in Q3, re-rating momentum could reignite.
While assessing USD/KRW volatility and macro capital flows into large-cap KOSPI names, closely tracking the Plant 5 ramp-up pace and regulatory disclosures of major supply contracts represents an effective approach.
---
FAQ
Q1. What is the operational schedule and expected revenue timeline for Plant 5?
Following completion, the 180,000L Plant 5 is undergoing validation batch production, with commercial revenue expected to be reflected sequentially starting in Q3 2026.
Q2. What is the current cumulative order backlog and client profile?
As of the end of Q2 2026, cumulative orders have exceeded $21.7 billion (approx. KRW 30 trillion), counting 16 of the top 20 global pharmaceutical companies as clients.
Q3. What is the purpose of the recently announced large-scale rights offering?
The approximately KRW 3 trillion rights offering was conducted to secure strategic growth capital, primarily for acquiring a stake in Switzerland-based PolyPeptide (approx. KRW 2.7 trillion) and expanding facilities at the Songdo Second Bio Campus.
Q4. How will the US Biosecure Act impact Samsung Biologics?
As Chinese CDMO companies face restrictions entering the US market, Samsung Biologics—with its proven track record and manufacturing quality—is well-positioned to capture spillover benefits as a prime alternative partner.
Q5. Have the production disruption issues from the H1 strike been resolved?
The company has stated that the delayed output of roughly KRW 150 billion will see some residual impact in Q3, but is expected to be largely recouped by Q4 through production rescheduling across the remainder of the year.
---